Correlation Between Collegium Pharmaceutical and Nautilus Biotechnology

Can any of the company-specific risk be diversified away by investing in both Collegium Pharmaceutical and Nautilus Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Collegium Pharmaceutical and Nautilus Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Collegium Pharmaceutical and Nautilus Biotechnology, you can compare the effects of market volatilities on Collegium Pharmaceutical and Nautilus Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Collegium Pharmaceutical with a short position of Nautilus Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Collegium Pharmaceutical and Nautilus Biotechnology.

Diversification Opportunities for Collegium Pharmaceutical and Nautilus Biotechnology

0.56

Correlation Coefficient

Collegium Pharmaceutical  Nautilus Biotechnology

Very weak diversification

The 3 months correlation between Collegium and Nautilus is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Collegium Pharmaceutical and Nautilus Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nautilus Biotechnology and Collegium Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Collegium Pharmaceutical are associated (or correlated) with Nautilus Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nautilus Biotechnology has no effect on the direction of Collegium Pharmaceutical i.e., Collegium Pharmaceutical and Nautilus Biotechnology go up and down completely randomly.

Pair Corralation between Collegium Pharmaceutical and Nautilus Biotechnology

Given the investment horizon of 90 days Collegium Pharmaceutical is expected to generate 0.58 times more return on investment than Nautilus Biotechnology. However, Collegium Pharmaceutical is 1.72 times less risky than Nautilus Biotechnology. It trades about 0.04 of its potential returns per unit of risk. Nautilus Biotechnology is currently generating about -0.2 per unit of risk. If you would invest  2,861  in Collegium Pharmaceutical on December 30, 2024 and sell it today you would earn a total of  110.00  from holding Collegium Pharmaceutical or generate 3.84% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Collegium Pharmaceutical  vs.  Nautilus Biotechnology

Collegium Pharmaceutical

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Collegium Pharmaceutical are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent essential indicators, Collegium Pharmaceutical is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors.

Nautilus Biotechnology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Nautilus Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Collegium Pharmaceutical and Nautilus Biotechnology

The main advantage of trading using opposite Collegium Pharmaceutical and Nautilus Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Collegium Pharmaceutical position performs unexpectedly, Nautilus Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nautilus Biotechnology will offset losses from the drop in Nautilus Biotechnology's long position.

The idea behind Collegium Pharmaceutical and Nautilus Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.